NO323231B1 - Soyaekstrakt, fremgangsmate for fremstilling derav og farmasoytisk blanding. - Google Patents
Soyaekstrakt, fremgangsmate for fremstilling derav og farmasoytisk blanding. Download PDFInfo
- Publication number
- NO323231B1 NO323231B1 NO20000399A NO20000399A NO323231B1 NO 323231 B1 NO323231 B1 NO 323231B1 NO 20000399 A NO20000399 A NO 20000399A NO 20000399 A NO20000399 A NO 20000399A NO 323231 B1 NO323231 B1 NO 323231B1
- Authority
- NO
- Norway
- Prior art keywords
- extract
- weight
- water
- treatment
- soy
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 17
- 230000008569 process Effects 0.000 title claims abstract description 7
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title description 10
- 235000020712 soy bean extract Nutrition 0.000 title 1
- 239000000284 extract Substances 0.000 claims abstract description 95
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims abstract description 57
- 235000008696 isoflavones Nutrition 0.000 claims abstract description 57
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 40
- -1 glucoside isoflavones Chemical class 0.000 claims abstract description 29
- 238000011282 treatment Methods 0.000 claims abstract description 27
- 229930182478 glucoside Natural products 0.000 claims abstract description 21
- 244000068988 Glycine max Species 0.000 claims abstract description 17
- 206010027304 Menopausal symptoms Diseases 0.000 claims abstract description 14
- 208000007848 Alcoholism Diseases 0.000 claims abstract description 13
- 201000007930 alcohol dependence Diseases 0.000 claims abstract description 10
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 8
- 201000011510 cancer Diseases 0.000 claims abstract description 6
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 claims abstract description 5
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 4
- 206010060862 Prostate cancer Diseases 0.000 claims abstract description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 78
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 31
- 239000000203 mixture Substances 0.000 claims description 25
- 150000002515 isoflavone derivatives Chemical class 0.000 claims description 24
- 229930188627 soysaponin Natural products 0.000 claims description 24
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 claims description 13
- 238000000605 extraction Methods 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 11
- 239000013543 active substance Substances 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 10
- 239000012074 organic phase Substances 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 229920005989 resin Polymers 0.000 claims description 7
- 239000011347 resin Substances 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 6
- 238000000746 purification Methods 0.000 claims description 6
- 238000001179 sorption measurement Methods 0.000 claims description 6
- 230000004048 modification Effects 0.000 claims description 5
- 238000012986 modification Methods 0.000 claims description 5
- 239000000010 aprotic solvent Substances 0.000 claims description 4
- 238000004090 dissolution Methods 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims description 3
- 239000004793 Polystyrene Substances 0.000 claims description 3
- 238000011010 flushing procedure Methods 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 229920002223 polystyrene Polymers 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 235000019764 Soybean Meal Nutrition 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 239000008346 aqueous phase Substances 0.000 claims description 2
- 238000007865 diluting Methods 0.000 claims description 2
- 238000010828 elution Methods 0.000 claims description 2
- 239000004455 soybean meal Substances 0.000 claims description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- 235000013312 flour Nutrition 0.000 abstract description 4
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 abstract 2
- 229930187719 Soyasaponin Natural products 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 235000012424 soybean oil Nutrition 0.000 abstract 1
- 235000019441 ethanol Nutrition 0.000 description 54
- 229930182490 saponin Natural products 0.000 description 21
- 150000007949 saponins Chemical class 0.000 description 21
- 235000017709 saponins Nutrition 0.000 description 21
- 230000000694 effects Effects 0.000 description 14
- 102000009151 Luteinizing Hormone Human genes 0.000 description 10
- 108010073521 Luteinizing Hormone Proteins 0.000 description 10
- 229940040129 luteinizing hormone Drugs 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N Daidzein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 7
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 230000001028 anti-proliverative effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 4
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 206010060800 Hot flush Diseases 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 235000007240 daidzein Nutrition 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000009245 menopause Effects 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 2
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 2
- 206010010219 Compulsions Diseases 0.000 description 2
- GMTUGPYJRUMVTC-UHFFFAOYSA-N Daidzin Natural products OC(COc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3)C(O)C(O)C(O)C=O GMTUGPYJRUMVTC-UHFFFAOYSA-N 0.000 description 2
- KYQZWONCHDNPDP-UHFFFAOYSA-N Daidzoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-UHFFFAOYSA-N 0.000 description 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
- ZCOLJUOHXJRHDI-FZHKGVQDSA-N Genistein 7-O-glucoside Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)c1cc(O)c2C(=O)C(c3ccc(O)cc3)=COc2c1 ZCOLJUOHXJRHDI-FZHKGVQDSA-N 0.000 description 2
- CJPNHKPXZYYCME-UHFFFAOYSA-N Genistin Natural products OCC1OC(Oc2ccc(O)c3OC(=CC(=O)c23)c4ccc(O)cc4)C(O)C(O)C1O CJPNHKPXZYYCME-UHFFFAOYSA-N 0.000 description 2
- 208000033830 Hot Flashes Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- FEFAIBOZOKSLJR-UHFFFAOYSA-N Miltirone Chemical compound C1CCC(C)(C)C=2C1=C1C(=O)C(=O)C(C(C)C)=CC1=CC=2 FEFAIBOZOKSLJR-UHFFFAOYSA-N 0.000 description 2
- YCUNGEJJOMKCGZ-UHFFFAOYSA-N Pallidiflorin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC(O)=C2C1=O YCUNGEJJOMKCGZ-UHFFFAOYSA-N 0.000 description 2
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 2
- 206010001584 alcohol abuse Diseases 0.000 description 2
- 208000025746 alcohol use disease Diseases 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- KYQZWONCHDNPDP-QNDFHXLGSA-N daidzein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-QNDFHXLGSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 229940028334 follicle stimulating hormone Drugs 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 2
- 235000006539 genistein Nutrition 0.000 description 2
- 229940045109 genistein Drugs 0.000 description 2
- NNUVCMKMNCKPKN-UHFFFAOYSA-N glycitein Natural products COc1c(O)ccc2OC=C(C(=O)c12)c3ccc(O)cc3 NNUVCMKMNCKPKN-UHFFFAOYSA-N 0.000 description 2
- 235000008466 glycitein Nutrition 0.000 description 2
- DXYUAIFZCFRPTH-UHFFFAOYSA-N glycitein Chemical compound C1=C(O)C(OC)=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 DXYUAIFZCFRPTH-UHFFFAOYSA-N 0.000 description 2
- OZBAVEKZGSOMOJ-MIUGBVLSSA-N glycitin Chemical compound COC1=CC(C(C(C=2C=CC(O)=CC=2)=CO2)=O)=C2C=C1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O OZBAVEKZGSOMOJ-MIUGBVLSSA-N 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 235000021374 legumes Nutrition 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000008389 polyethoxylated castor oil Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000002747 voluntary effect Effects 0.000 description 2
- HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 1
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 1
- 229940084657 Benzodiazepine receptor inverse agonist Drugs 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- XJTZHGNBKZYODI-UHFFFAOYSA-N Glycitin Natural products OCC1OC(Oc2ccc3OC=C(C(=O)c3c2CO)c4ccc(O)cc4)C(O)C(O)C1O XJTZHGNBKZYODI-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010067572 Oestrogenic effect Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 244000046146 Pueraria lobata Species 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- 241000304195 Salvia miltiorrhiza Species 0.000 description 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229930183118 Tanshinone Natural products 0.000 description 1
- YTAHJIFKAKIKAV-XNMGPUDCSA-N [(1R)-3-morpholin-4-yl-1-phenylpropyl] N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]carbamate Chemical compound O=C1[C@H](N=C(C2=C(N1)C=CC=C2)C1=CC=CC=C1)NC(O[C@H](CCN1CCOCC1)C1=CC=CC=C1)=O YTAHJIFKAKIKAV-XNMGPUDCSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000755 benzodiazepine receptor inverse stimulating agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- BTZJQYVYGCCNHY-UHFFFAOYSA-N calcium;urea Chemical compound [Ca].NC(N)=O BTZJQYVYGCCNHY-UHFFFAOYSA-N 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000007073 chemical hydrolysis Effects 0.000 description 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000005115 demineralization Methods 0.000 description 1
- 230000002328 demineralizing effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229960002563 disulfiram Drugs 0.000 description 1
- 150000004141 diterpene derivatives Chemical class 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000002895 emetic Substances 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229930012930 isoflavone derivative Natural products 0.000 description 1
- 229960004427 isradipine Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920005990 polystyrene resin Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Oncology (AREA)
- Addiction (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE1997132822 DE19732822C2 (de) | 1997-07-30 | 1997-07-30 | Soja-Extrakt, dessen Herstellungsverfahren und diesen enthaltende pharmazeutische Zusammensetzungen und deren Verwendung für die Prävention oder Behandlung von Alkoholismus |
| DE1997132866 DE19732866C2 (de) | 1997-07-30 | 1997-07-30 | Neue Soja-Extrakte, ihre Herstellung, auf ihnen basierende Formulierungen und deren Verwendung für die Prävention oder Behandlung von pre-menopausalen und post-menopausalen Symptomen |
| DE1997132855 DE19732855C2 (de) | 1997-07-30 | 1997-07-30 | Spezieller Soja-Extrakt, dessen Herstellung, diesen enthaltende Formulierungen und deren Verwendung für die Prävention oder Behandlung von Krebs |
| PCT/EP1998/004770 WO1999006057A1 (en) | 1997-07-30 | 1998-07-30 | Soya extract, process for its preparation and pharmaceutical composition |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20000399L NO20000399L (no) | 2000-01-26 |
| NO20000399D0 NO20000399D0 (no) | 2000-01-26 |
| NO323231B1 true NO323231B1 (no) | 2007-02-05 |
Family
ID=27217588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20000399A NO323231B1 (no) | 1997-07-30 | 2000-01-26 | Soyaekstrakt, fremgangsmate for fremstilling derav og farmasoytisk blanding. |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US6280777B1 (zh) |
| EP (1) | EP1001797B9 (zh) |
| JP (2) | JP3570989B2 (zh) |
| KR (1) | KR100388511B1 (zh) |
| CN (1) | CN1089245C (zh) |
| AT (1) | ATE297213T1 (zh) |
| AU (1) | AU740356B2 (zh) |
| CA (1) | CA2298142C (zh) |
| CZ (1) | CZ298532B6 (zh) |
| DE (1) | DE69830495T2 (zh) |
| DK (1) | DK1001797T3 (zh) |
| ES (1) | ES2243005T3 (zh) |
| HK (1) | HK1025507A1 (zh) |
| HU (1) | HU229444B1 (zh) |
| NO (1) | NO323231B1 (zh) |
| PL (1) | PL191191B1 (zh) |
| PT (1) | PT1001797E (zh) |
| RU (1) | RU2183964C2 (zh) |
| SK (1) | SK283491B6 (zh) |
| WO (1) | WO1999006057A1 (zh) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6261565B1 (en) * | 1996-03-13 | 2001-07-17 | Archer Daniels Midland Company | Method of preparing and using isoflavones |
| CN1089245C (zh) * | 1997-07-30 | 2002-08-21 | 因迪纳有限公司 | 大豆提取物、其制备方法及其药物组合物 |
| JP4913968B2 (ja) * | 1999-07-09 | 2012-04-11 | サン ファーム コーポレイション | 栄養補助食品を用いた悪性疾患およびウイルス感染を処置および免疫機能を改善する方法 |
| CA2391247C (en) * | 1999-12-17 | 2010-07-20 | Mitsunori Ono | Water-soluble bean-based extracts |
| JP2004517801A (ja) * | 2000-04-18 | 2004-06-17 | セテリス・ホールディング・ベスローテン・フェンノートシャップ−アムステルダム（オランダ）−スックルサーレ・ディ・ルガーノ | 皮膚のしわの予防または治療に有用な天然抽出物に基づく組成物 |
| CN1096456C (zh) * | 2000-06-08 | 2002-12-18 | 蒋宇扬 | 连续提取大豆异黄酮、低聚糖、皂甙的工艺 |
| KR20010016220A (ko) * | 2000-11-17 | 2001-03-05 | 이광필 | 대두 배아로부터 생리활성 물질인 이소플라본의 분리정제방법 |
| FR2818096B1 (fr) * | 2000-12-14 | 2004-05-07 | Daniel Chajuss | Composition phytochimique de soja |
| IL148825A0 (en) * | 2002-03-21 | 2002-09-12 | Yeda Res & Dev | Derivatives of isoflavones |
| US20040131749A1 (en) * | 2002-08-29 | 2004-07-08 | Archer-Daniels-Midland Company | Phytochemicals from edible bean process streams |
| ITMI20022723A1 (it) * | 2002-12-20 | 2004-06-21 | Marfarma S R L Ora Marfarma Holding Spa | Composizioni per il trattamento della sindrome post-menopausa. |
| CN100591225C (zh) * | 2002-12-24 | 2010-02-24 | 不二制油株式会社 | 含有高浓度的异黄酮并具有高溶解度的组合物及其制备方法 |
| GB0317020D0 (en) * | 2003-07-21 | 2003-08-27 | Sahajanand Biotech Private Ltd | Herbo-mineral formulation for refractory leukemias and lymphomas |
| US7718813B2 (en) | 2003-08-15 | 2010-05-18 | Nature Pure Labs Sw, Inc. | Hydrolysis and purification of active plant compounds suitable for topical application |
| AU2004287358A1 (en) | 2003-09-08 | 2005-05-19 | Genyous Biomed International Inc. | Compositions of botanical extracts for cancer therapy |
| CN1878471A (zh) * | 2003-09-22 | 2006-12-13 | 盖尼奥斯生物医学国际公司 | 用于癌症治疗的沙棘组合物 |
| KR100449887B1 (ko) * | 2003-10-31 | 2004-09-22 | 주식회사 렉스진바이오텍 | 이소플라본을 함유하는 괴각 추출물의 제조방법 |
| MD2518G2 (ro) * | 2003-12-09 | 2005-06-30 | Элеонора ВАТАМАН | Preparat medicamentos pentru reducerea concentratiei colesterolului in sange |
| JP2005232032A (ja) * | 2004-02-17 | 2005-09-02 | Kikkoman Corp | 敗血症の予防・治療剤 |
| WO2005084340A2 (en) * | 2004-03-03 | 2005-09-15 | Bio-Botanica, Inc. | Pueraria candollei var. mirifica a shaw. & suvat. extract |
| EP1750732B1 (en) | 2004-05-10 | 2013-03-27 | Instituto Tecnologico y de Estudios Superiores de Monterrey | Cancer cell growth inhibition by black bean (phaseolus vulgaris l.) extracts |
| AU2005203059B2 (en) * | 2004-07-16 | 2011-11-24 | Johnson & Johnson Consumer Companies, Inc. | Use of legume products for the treatment and prevention of radiotherapy-induced skin damage |
| AU2005229653B2 (en) * | 2004-11-02 | 2006-06-08 | Finocchiaro, Rosario Salvatore Antonio | Wood cutting tool |
| CN100345505C (zh) * | 2004-12-21 | 2007-10-31 | 山东理工大学 | 提取大豆异黄酮、皂甙、低聚糖的挤压加工方法和装置 |
| KR20070119669A (ko) * | 2005-03-09 | 2007-12-20 | 카아길, 인코포레이팃드 | 유지종자를 추출하는 방법 및 얻어지는 생성물의 용도 |
| AU2007227535A1 (en) * | 2006-03-15 | 2007-09-27 | Rutgers, The State University Of New Jersey | Hydroxylated polymethoxyflavone compositions |
| US20110117121A1 (en) * | 2006-10-27 | 2011-05-19 | James Dao | Compositions for treatment and inhibition of pain |
| WO2008052754A2 (de) * | 2006-11-02 | 2008-05-08 | Dr. Willmar Schwabe Gmbh & Co. Kg | Verfahren zur herstellung von pflanzenextrakten mit vermindertem gehalt an umweltbedingten unpolaren fremdstoffen |
| WO2008057934A1 (en) * | 2006-11-03 | 2008-05-15 | Corn Products International, Inc. | Encapsulated soy extracts and process for preparing same |
| CA2710022A1 (en) * | 2008-01-03 | 2009-07-16 | Monsanto Technology Llc | Method of selecting soybeans with enhanced bioactivity and compositions for reducing cancer cell viability |
| EP2285821B1 (en) * | 2008-06-17 | 2014-12-17 | Pawan Kumar Goel | A novel process for extraction of furostanolic saponins from fenugreek seeds |
| CN101477098B (zh) * | 2009-01-08 | 2012-07-18 | 上海交通大学 | 利用大豆天然提取物检测大豆抗蚜性的方法 |
| CN102548565A (zh) * | 2009-10-22 | 2012-07-04 | 株式会社益力多本社 | 癌症发病风险降低剂 |
| CN102977066A (zh) * | 2012-12-07 | 2013-03-20 | 山东大学 | 大豆中异黄酮的提取与纯化方法 |
| EP3085226B1 (en) * | 2013-12-13 | 2020-09-09 | Industry-Academic Cooperation Foundation Gyeongsang National University | Bean leaves or bean stems having high isoflavone derivative content, and method for preparing same |
| KR101834766B1 (ko) * | 2014-09-26 | 2018-03-08 | 대한민국 | 향상된 색택을 가지는 콩 유래 추출물 |
| KR101834764B1 (ko) * | 2014-09-26 | 2018-03-08 | 대한민국 | 유효성분의 함량이 향상된 콩 유래 추출물 |
| US10543243B2 (en) | 2016-06-06 | 2020-01-28 | Charsire Biotechnology Corp. | Soybeam seed extract, method for producing the same and uses thereof |
| RU2664148C1 (ru) * | 2017-09-11 | 2018-08-15 | Павел Павлович Хорошутин | Способ производства сухих экстрактов из сырья растительного происхождения |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4501734A (en) * | 1981-03-06 | 1985-02-26 | Wakunaga Yakuhin Kabushiki Kaisha | Promotion of absorption of drugs administered through the alimentary system |
| JPS5933232A (ja) | 1982-08-19 | 1984-02-23 | Tokiwa Kanpou Seiyaku:Kk | マメ科植物からサポニン類およびフラボン類の分離方法 |
| JPS5988064A (ja) | 1982-11-10 | 1984-05-21 | Osaka Chem Lab | 美容食品 |
| JPS59175496A (ja) | 1983-03-23 | 1984-10-04 | Osaka Chem Lab | ソ−ヤサポニンの単離法 |
| JPS6136225A (ja) * | 1984-07-30 | 1986-02-20 | Airin:Kk | サポニン類の単離法 |
| JPS625917A (ja) * | 1985-07-03 | 1987-01-12 | Airin:Kk | 大豆胚芽よりのイソフラボン類を含有しないサポニンの製造法 |
| JPS63245648A (ja) * | 1987-04-01 | 1988-10-12 | Ajinomoto Co Inc | 大豆食品素材の製法 |
| CH679584A5 (zh) * | 1989-11-10 | 1992-03-13 | Nestle Sa | |
| JPH0436242A (ja) * | 1990-05-30 | 1992-02-06 | Fuji Oil Co Ltd | 大豆サポニンの製造法 |
| US5204369A (en) | 1991-07-01 | 1993-04-20 | The Endowment For Research In Human Biology | Method for the inhibition of aldh-i useful in the treatment of alcohol dependence or alcohol abuse |
| NZ252051A (en) * | 1992-05-19 | 1996-10-28 | Graham Edmund Kelly | Health supplement comprising a phyto-oestrogen selected from genistein, daidzein, biochanin and/or formononetin |
| JPH06136225A (ja) | 1992-10-29 | 1994-05-17 | Sanyo Chem Ind Ltd | 水溶性高分子化合物の水分散液 |
| JP3078694B2 (ja) * | 1993-12-17 | 2000-08-21 | キッコーマン株式会社 | ゲニステインの製造法 |
| AU3689095A (en) | 1994-10-03 | 1996-04-26 | Schouten Industries B.V. | Food and health products |
| JPH08291191A (ja) * | 1995-04-24 | 1996-11-05 | Kikkoman Corp | アセチルイソフラボン配糖体の製造法 |
| IT1274481B (it) | 1995-05-12 | 1997-07-17 | Indena Spa | Composizioni farmaceutiche per il trattamento della alcol-dipendenza |
| IT1275436B (it) | 1995-05-19 | 1997-08-07 | Indena Spa | Uso della forskolina e di estratti che la contengono per il trattamento della alcol-dipendenza |
| US6020471A (en) * | 1996-09-13 | 2000-02-01 | Abbott Laboratories | Process for isolating phytoestrogens from plant protein |
| CN1089245C (zh) * | 1997-07-30 | 2002-08-21 | 因迪纳有限公司 | 大豆提取物、其制备方法及其药物组合物 |
-
1998
- 1998-07-30 CN CN98807664A patent/CN1089245C/zh not_active Expired - Fee Related
- 1998-07-30 KR KR10-2000-7001016A patent/KR100388511B1/ko not_active IP Right Cessation
- 1998-07-30 PL PL337520A patent/PL191191B1/pl unknown
- 1998-07-30 CZ CZ20000223A patent/CZ298532B6/cs not_active IP Right Cessation
- 1998-07-30 ES ES98942659T patent/ES2243005T3/es not_active Expired - Lifetime
- 1998-07-30 DK DK98942659T patent/DK1001797T3/da active
- 1998-07-30 PT PT98942659T patent/PT1001797E/pt unknown
- 1998-07-30 SK SK104-2000A patent/SK283491B6/sk not_active IP Right Cessation
- 1998-07-30 EP EP98942659A patent/EP1001797B9/en not_active Expired - Lifetime
- 1998-07-30 CA CA002298142A patent/CA2298142C/en not_active Expired - Fee Related
- 1998-07-30 RU RU2000105259/14A patent/RU2183964C2/ru not_active IP Right Cessation
- 1998-07-30 WO PCT/EP1998/004770 patent/WO1999006057A1/en active IP Right Grant
- 1998-07-30 JP JP2000504870A patent/JP3570989B2/ja not_active Expired - Fee Related
- 1998-07-30 AU AU90711/98A patent/AU740356B2/en not_active Ceased
- 1998-07-30 HU HU0003058A patent/HU229444B1/hu not_active IP Right Cessation
- 1998-07-30 DE DE69830495T patent/DE69830495T2/de not_active Expired - Lifetime
- 1998-07-30 AT AT98942659T patent/ATE297213T1/de active
-
2000
- 2000-01-26 NO NO20000399A patent/NO323231B1/no not_active IP Right Cessation
- 2000-01-28 US US09/492,921 patent/US6280777B1/en not_active Expired - Lifetime
- 2000-07-04 HK HK00104037A patent/HK1025507A1/xx not_active IP Right Cessation
-
2001
- 2001-07-11 US US09/902,226 patent/US6607757B2/en not_active Expired - Lifetime
-
2002
- 2002-04-23 JP JP2002120590A patent/JP2003002838A/ja active Pending
-
2003
- 2003-06-30 US US10/608,213 patent/US7108871B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO323231B1 (no) | Soyaekstrakt, fremgangsmate for fremstilling derav og farmasoytisk blanding. | |
| US6017893A (en) | Use of isoflavones to prevent hair loss and preserve the integrity of existing hair | |
| US6399579B1 (en) | Compositions comprising icariside I and anhydroicaritin and methods for making the same | |
| JP2004002304A (ja) | フィト−エストロゲン、類似体の健康補助剤製造のための使用方法 | |
| NO318696B1 (no) | Ernærings- eller mattilskuddsblanding samt anvendelse derav, for fremstilling av doseringsform. | |
| KR100934022B1 (ko) | 에스트로겐 활성이 우수한 보골지 추출물 또는 상기 보골지추출물로부터 분리한 활성성분을 포함하는 조성물 | |
| KR100348147B1 (ko) | 골다공증 예방 및 치료에 효과를 갖는 갈근 추출물 | |
| Ammar et al. | Phytochemical and biological studies of butea frondosa Roxb. leaves growing in Egypt | |
| KR102077612B1 (ko) | 에스트로겐 활성 및 유방암 억제 효능을 지닌 복분자 추출물 및 sanguiin H-6 그리고 이의 제조방법 | |
| KR20190113127A (ko) | 레드클로버 추출물을 함유하는 여성갱년기 개선용 조성물 | |
| Pullaiah | Forskolin | |
| CN112168892B (zh) | 一种用于改善围绝经期妇女综合征症的中药组合物 | |
| Udgata et al. | Soybean isoflavones: Remedial nutraceuticals in Indian perspective | |
| KR100348148B1 (ko) | 골다공증 예방 및 치료에 효과를 갖는 갈근 추출물 | |
| Al–Zubaide et al. | EFFECT OF METHANOL EXTRACT OF ALTHAEA OFFICINALIS L. FLOWERS ON ESTROGEN AND OVARY OF RATS | |
| TWI260205B (en) | A composition including isoflavones refined from plant | |
| AU777561B2 (en) | Health supplements containing phyto-oestrogen, analogues or metabolites thereof | |
| JP2001342132A (ja) | 乳癌を予防し、もしくは治療するための組成物およびそのための方法 | |
| MXPA99009930A (en) | Preparation of isoflavones from legumes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |